Autolus Therapeutics plc 8-K

What Happened
On April 8, 2026, Autolus Therapeutics plc announced it hosted a virtual investor event titled “Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business” and posted the event presentation to its website. The company furnished the presentation as Exhibit 99.1 to a Form 8-K filed the same day under Item 7.01 (Regulation FD disclosure). The filing is signed by CEO Christian Itin, Ph.D.

Key Details

• Event date: April 8, 2026 — virtual investor event titled “Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business.”
• Presentation: Posted to Autolus’ website and attached to the 8-K as Exhibit 99.1 (incorporated by reference).
• Filing: Form 8-K filed April 8, 2026, disclosed under Item 7.01 (Regulation FD).
• Signature: Report signed by Christian Itin, Ph.D., Chief Executive Officer.

Why It Matters
This 8-K publicly shares Autolus’ investor presentation on its ALL business, giving all investors equal access to the company’s update on strategy, pipeline and related information contained in the slides. Because the disclosure was made under Regulation FD, the information was provided in a manner intended to ensure fair public access rather than selective disclosure. Investors should review the posted presentation (Exhibit 99.1) for specifics on programs, timelines or any data included; the filing does not report earnings or other financial results.